Registration Dossier

Diss Factsheets

Administrative data

Description of key information

The skin sensitising potential of 6FDA was evaluated by obtaining predictions using the automated workflow in the OECD QSAR Toolbox after a review of the literature did not identify usable experimental data.


As alerts were returned from the initial profiling, predictions were made from Guinea Pig Maximisation Test and the Local Lymph Node Assay (LLNA) with substances leading to acylation upon protein binding according to the "Protein binding alerts for skin sensitisation by OASIS" profiler. The result of the prediction was positive. It was therefore concluded that 6FDA can be expected to induce skin sensitisation. Furthermore, the analogous substances that have been identified and that support this prediction are classified as moderate to strong skin sensitisers, according to the GHS classification regulation and CLP regulation 1272/2008 , they are classified as Skin Sens. Category 1A. Therefore, it can be expected that 6FDA such as its analogues may be classified as Skin Sens. Category 1A.

Key value for chemical safety assessment

Skin sensitisation

Link to relevant study records
Reference
Endpoint:
skin sensitisation, other
Type of information:
other: Expert Assessment
Adequacy of study:
weight of evidence
Study period:
March 2022
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Based on structural alerts and QSAR models
Qualifier:
no guideline followed
Principles of method if other than guideline:
An expert assesment was performed uses information from the OECD QSAR Toolbox which uses read-across and numerous databases of experimental results to enable the user to fill in data gaps in a logical workflow. Relevant information for the target substance, including probable mechanisms of action and observed/simulated metabolites, is retrieved by profiling to contribute to data gathering and the identification of suitable analogues, and by grouping substances into meaningful categories according to structural similarities. The OECD QSAR Toolbox is outlined by ECHA as one of the in silico tools to reliably predict skin sensitisation.
GLP compliance:
no
Type of study:
other: Structural alerts and QSAR models
Key result
Group:
test chemical
Run / experiment:
other: N/A
Parameter:
other: QSAR predicition
Remarks on result:
positive indication of skin sensitisation

Profiling returned alerts for “Protein binding alerts for skin sensitisation according to GHS” (Skin sensitization Category 1A;Skin sensitization Category 1A >> Anhydrides (sulphur analogues of anhydrides)), “Protein binding alerts for skin sensitization by OASIS” (Acylation), “Protein binding potency h-CLAT” (Acid anhydride), “Protein binding by OASIS” (Acylation), “Protein binding by OECD” (Acylation), “Protein binding potency GHS” (Moderately reactive (GSH);Moderately reactive (GSH) >> Anhydrides and Lactones (SN2 ring opening)) and “Protein binding potency Lys (DPRA 13%)” (DPRA above 21% (DPRA 13%);DPRA above 21% (DPRA 13%) >> Cyclic acid anhydrides).


 


Based on substances with the same protein binding mechanism, i.e. "Acylation", according to the "Protein binding alerts for skin sensitisation by OASIS" profile, a positive prediction was obtained with a predictive confidence measured by the p-value of 0.5. The estimation was based on five values and three of them (60%) were equal to the predicted value.

Interpretation of results:
Category 1A (indication of significant skin sensitising potential) based on GHS criteria
Conclusions:
6FDA is expected to be a category 1A skin sensitiser.
Executive summary:

The skin sensitising potential of 6FDA was evaluated by obtaining predictions using the automated workflow in the OECD QSAR Toolbox after a review of the literature did not identify usable experimental data.


As alerts were returned from the initial profiling, predictions were made from Guinea Pig Maximisation Test and the Local Lymph Node Assay (LLNA) with substances leading to acylation upon protein binding according to the "Protein binding alerts for skin sensitisation by OASIS" profiler. The result of the prediction was positive. It was therefore concluded that 6FDA can be expected to induce skin sensitisation. Furthermore, the analogous substances that have been identified and that support this prediction are classified as moderate to strong skin sensitisers, according to the GHS classification regulation and CLP regulation 1272/2008 , they are classified as Skin Sens. Category 1A. Therefore, it can be expected that 6FDA such as its analogues may be classified as Skin Sens. Category 1A.

Endpoint conclusion
Endpoint conclusion:
adverse effect observed (sensitising)

Justification for classification or non-classification

The skin sensitising potential of 6FDA was evaluated by obtaining predictions using the automated workflow in the OECD QSAR Toolbox after a review of the literature did not identify usable experimental data.


As alerts were returned from the initial profiling, predictions were made from Guinea Pig Maximisation Test and the Local Lymph Node Assay (LLNA) with substances leading to acylation upon protein binding according to the "Protein binding alerts for skin sensitisation by OASIS" profiler. The result of the prediction was positive. It was therefore concluded that 6FDA can be expected to induce skin sensitisation. Furthermore, the analogous substances that have been identified and that support this prediction are classified as moderate to strong skin sensitisers, according to the GHS classification regulation and CLP regulation 1272/2008 , they are classified as Skin Sens. Category 1A. Therefore, it can be expected that 6FDA such as its analogues may be classified as Skin Sens. Category 1A.